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Abbreviations: 
ALD= Alcoholic liver disease; ALT = alanine aminotransferase; AST = aspartame aminotransferase; APRI = 
AST:platelet count ratio; AUDIT = Alcohol use disorders identification test;  BAAT = score of age≥50 years (1 
point), body mass index≥28 kg/m2 (1 point), ALT≥2 times upper limit of normal, triglycerides≥1.7mmol/L; BARD = 
weighted score of Body mass index ≥28kg/m2 (1 point), AST:ALT ratio≥0.8 (2 points), Type 2 Diabetes (1 point); 
BMI = body mass index; EASL = European association for the study of liver;  ELF = Enhanced Liver Fibrosis 
(combination of hyaluronic acid, TIMP metallopeptidase inhibitor 1 and Procollagen III N-Terminal 
Propeptide);FIB4 = combination of age, ALT, AST and platelet count; kPa = kilopascals; LFTs = Liver function tests; 
MeSH = Medical subject headings; NAFLD = Non-alcoholic fatty liver disease; NASH = Non-alcoholic 
steatohepatits; NFS = NAFLD Fibrosis Score (combination of age, hyperglycaemia, body mass index, platelet 
count, albumin, and AST:ALT ratio); OR = Odds Ratio; TE = Transient Elastography; UK= United Kingdom 
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Summary 
At present, there is no evidence based pathway to stratify risk of chronic liver disease in a general 
population setting.  Non-invasive tests of liver fibrosis may provide a mechanism for earlier diagnosis. 
These tests have been extensively validated in the hospital setting but their performance in a general 
population setting is unclear. We performed a systematic review of non-invasive tests used to stratify 
patients at risk of clinically significant liver disease in a general population setting and report the 
prevalence of chronic liver disease as defined by these tests. We systematically searched EMBASE, 
MEDLINE, Web of Science, reference lists from the original studies and recent conference proceedings. 
All study designs were considered. Nineteen studies were identified, utilising eleven non-invasive 
tests. Only transient elastography and Fibrotest were compared against histological end-points. The 
prevalence of liver fibrosis varied between 0.7% and 25.7%. More focussed stratification for advanced 
liver fibrosis (0.9%-2%) or cirrhosis (0.1%-1.7%) narrowed estimates of prevalence. Studies targeting 
patients with liver disease risk factors such as hazardous alcohol use or type 2 diabetes reported 
higher prevalence of advanced liver fibrosis (0%-27.9%) and cirrhosis (2.4%-4%).  Validated non-
invasive tests of liver fibrosis consistently detected otherwise unrecognised liver disease in the general 
population. Studies targeting risk factors found cirrhosis in 2.4 to 4 % of their target populations. 
Reliance on abnormal liver function tests will miss the majority of patients with significant liver injury. 
New pathways to stratify chronic liver, using non-invasive markers of liver fibrosis, are needed in the 
general population setting. 
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Introduction 
 
Chronic liver disease has become an increasing health burden worldwide. In 2015, cirrhosis and 
chronic liver diseases accounted for 2% of worldwide deaths, with a relative increase of 10.3% from 
2005(1). There are significant variations in mortality among different regions of the world with 
Mokdad et al(2) reporting liver cirrhosis as a health priority in Central Asia, Central Europe, Eastern 
Europe and Central Latin America. Increasing mortality rates are attributable to viral hepatitis but also 
driven by the increasing prevalence of alcoholic liver disease (ALD) and non-alcoholic fatty liver disease 
(NAFLD) which are now the most common causes of chronic liver disease in the Western world(3-5).       
 
Due to the increasing morbidity and mortality of chronic liver disease there is a necessity for urgent 
action to be taken to prioritise the earlier identification and treatment of patients, particularly within 
the community(6). Commonly used diagnostic tests have poor sensitivity and specificity, are 
completed opportunistically or are not appropriate to be used within a community setting therefore 
limiting the opportunities for intervening at an earlier stage in the disease. This results in nearly 50% 
of patients only receiving their diagnosis of cirrhosis following an emergency admission to hospital 
with a decompensating event(7).  A liver biochemistry panel often referred to as Liver function tests 
(LFTs) are inappropriately relied upon in the community setting to identify patients with asymptomatic 
chronic liver disease(8-10). Fracanzani et al(11) demonstrated that 59% of patients with a histological 
diagnosis of NASH had a normal serum alanine aminotransferase (ALT) level and would not have been 
identified by current diagnostic algorithms.  
 
At present, an evidenced based risk stratification pathway does not exist within a community setting 
to screen the general or a targeted population who are at risk of chronic liver disease. Until recently a 
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barrier has been the absence of a robust and reproducible screening tool. Non-invasive tests of liver 
fibrosis represent such a tool and their utility in hospital practice has been supported by a number of 
international organisations including recent guidelines by EASL(12). However, the majority of evidence 
has been derived and validated from populations based within secondary care (13-15)  and thus 
extrapolation of these tests to a cohort in the community may not be valid due to a reliance upon 
abnormal LFTs instigating referral for specialist advice, a different prevalence of disease and spectrum 
bias.   
 
To facilitate the emergence of strategies which aim to risk stratify patients in a general 
population/community setting we have systematically reviewed the available evidence. From this, the 
scale of undiagnosed chronic liver disease can be estimated, the inadequacy of current referral 
pathways can be highlighted and an optimal risk stratification strategy potentially proposed. As the 
commonest causes of chronic liver disease are ALD and NAFLD we have focussed on the non-invasive 
tests which have been used to stratify patients at risk of these aetiologies.   
Aims 
 
The primary aim of this systematic review was to determine the proportion of the studied populations 
found to have clinically significant liver disease as defined by the non-invasive tests used in the 
individual studies.  
The secondary aims of this systematic review were i) to identify the proportion of patients with liver 
fibrosis or cirrhosis as defined by the non-invasive test who had normal ALT results, ii) to evaluate the 
difference in the proportion of patients identified as having liver disease using non-invasive tests 
between unselected or targeted populations within a community setting and iii) to determine the 
patient variables which are significant in identifying patients with liver fibrosis. 
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Methods 
 
This review was conducted in accordance with the Cochrane Handbook for Systematic Reviews of 
interventions(16) and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRIMSA) guidelines(17).  
Search strategy 
 
Two reviewers (RH and DH) defined key MeSH headings and free text search terms relevant to the 
participants involved in the studies, the two aetiologies of chronic liver disease, the community setting 
and the non-invasive tests used to stratify for liver fibrosis. Subsequently, a search algorithm was 
derived in collaboration with a local librarian (Alison Ashmore; University of Nottingham); the final 
search algorithms including the MeSH terms used within the specific electronic databases are listed 
within the appendix. Two independent searches of EMBASE (January 1980 to January 2015), MEDLINE 
(January 1946 to January 2015) and Web of Science were completed. Additionally a hand search was 
completed of all major UK and worldwide conference proceedings dating back to 2010 including the 
British Society of Gastroenterology, the British Association for the study of liver disease, the European 
Association for the study of liver disease and the American Association for the study of liver disease.  A 
targeted search was also completed of reference lists from the original studies and abstracts including 
any review articles or citations that were identified.  
 
Identification of studies was commenced in November 2014 and completed in January 2015. The titles 
and abstracts of all studies identified within the literature search were screened to determine their 
suitability for inclusion within the review. The full texts of all studies considered to be suitable were 
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assessed for eligibility. Any disagreements were discussed but if these could not be resolved the 
advice from a third reviewer (ING) was sought.  
Selection criteria 
 
Listed below are the eligibility criteria used to screen the individual studies for inclusion within the 
review.  
 
Studies were included if: i) the study was performed in adults defined as 18 years or older, ii) the study 
population was from a non-hospital setting e.g. community, primary care or outreach unit, iii) study 
participants underwent a validated non-invasive test which would stratify for liver fibrosis, iv) the 
prevalence of clinically significant liver disease, either liver fibrosis or cirrhosis was reported as an 
outcome measure by the study (validation of the result by histopathology was not an absolute 
requirement) and v) participants were recruited from an unselected population or based upon the 
participants age or a defined risk factor for ALD or NAFLD. 
 
Studies were excluded if: i) data regarding the study population, the setting in which the non-invasive 
test was completed or the threshold for the non-invasive test was not adequately reported, ii) the 
participants were solely investigated for liver disease aetiologies other than ALD or NAFLD (e.g. viral 
hepatitis) or iii) they were not published in the English language 
 
 
Data collection and analysis 
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Data extraction was completed and reviewed by the two researchers independently. This included 
data on study characteristics, demographics of the patient population and details of the non-invasive 
test which was used. The outcome measure was the reported prevalence of liver fibrosis and/or 
cirrhosis within the population studied as defined by the non-invasive test which was used.  Due to the 
lack of comparable studies and substantial heterogeneity a meta-analysis could not be performed.  
 
 
 Figure 1. Flow diagram of the article search strategy and selection of studies eligible for data analysis 
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Results 
 
Our systematic search of bibliographic databases identified a total of 813 citations. An additional 7 
studies were identified from the grey literature. Following screening of the titles and abstracts, a total 
of 779 studies were excluded. The full text of 41 studies was assessed against the inclusion and 
exclusion criteria resulting in a further 22 studies being excluded from the final analysis. Finally, 19 
studies including 17 full journal articles and 2 abstracts were included within the systematic review. 
The overall results of the search strategy are presented in figure 1. 
 
Non-invasive tests used: 
Eleven different non-invasive tests were utilised to stratify patients for liver fibrosis. Transient 
elastography (TE) was the only imaging based modality and was the most frequently used test 
included within 12 out of the 19 studies identified. The majority of studies reported performance using 
the M probe with one study reporting performance of both M and XL probes. The remaining non-
invasive tests were all serum based and comprised NAFLD fibrosis score (NFS), used within 5 studies, 
Fibrotest, used within 3, the BARD score (BARD = weighted score of Body mass index ≥28kg/m2 (1 
point), AST:ALT ratio≥0.8 (2 points), Type 2 Diabetes (1 point)) ; AST:ALT ratio, APRI score (APRI = 
AST:platelet count ratio) and the FIB4 index (FIB4 = combination of age, ALT, AST and platelet 
count) which were used within 2 and the BAAT score (BAAT = score of age≥50 years (1 point), 
body mass index≥28 kg/m2 (1 point)) , Hyaluronic acid, the ELF score (enhanced liver fibrosis)  and 
the Southampton traffic light test which were all used once within separate studies. The baseline 
characteristics of individual studies including patient demographics are reported within Table 1. 
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Target population: 
There was significant heterogeneity in the community studies included for analysis (Table 1). The 
initial target population tested by the non-invasive tests varied. Five studies stratified members of the 
general population according to an age cut off whilst a further 5 studies stratified an unselected group 
of adults. The prevalence of risk factors reported within these studies would be as expected for the 
general population apart from the study by You et al(18) in which the prevalence of type 2 diabetes 
was raised at 11.9%. Ten studies stratified patients with risk factors for NAFLD including 3 studies(19-
21) which completed subgroup analysis on patients initially identified from the general population. 
Four studies stratified patients known to be at risk of ALD including 1 study(19) which had completed 
further subgroup analysis. Heterogeneity also existed in the choice of non-invasive test and outcome 
measure, including the severity of liver fibrosis.  
 
Screening uptake 
The proportion of patients that participated in screening from the invited study population was 
reported in eight studies. This ranged from 20%-89% for the first study visit. In studies which had 
multiple steps within the algorithm(22,23) a decline in uptake was observed. In the study by Sheron et 
al(22) a positive AUDIT questionnaire was recorded in 24.3%, however only 34.8% of this group 
subsequently attended clinic for the non-invasive test to be completed.  
 
Prevalence of fibrosis 
 
All 19 studies reported the prevalence of liver fibrosis according to a specified threshold for the non-
invasive test which was utilised.  
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Unselected population  
 
In those studies reporting unselected patients from the general population the prevalence of liver 
fibrosis ranged from 2%-19% (Table 2). All 5 studies utilised TE but the results varied due to the 
different liver stiffness thresholds that were chosen and the degree of liver fibrosis that was 
estimated. The lowest estimate obtained in the study by Wong et al(20) used the highest threshold of 
9.6kPa and estimated the prevalence of advanced liver fibrosis only. The highest estimate in the study 
by Malik et al(24), used a lower threshold of 7.0kPa and estimated the prevalence for any liver fibrosis. 
In the 5 studies which stratified members of the general population according to an age cut off, the 
prevalence ranged from 0.7%-25.7%. The lowest estimate obtained in the study by Poynard et al(23) 
used a two-step approach with only half of the patients re-attending for the second test. Overall only 
two studies stratified members of the general population for advanced liver fibrosis. The reported 
prevalence was 0.9%(25) and 2%(20) using Fibrotest ≥0.59 and TE ≥ 9.6kPa respectively. 
 
NAFLD 
 
In the ten studies which stratified patients identified to be at risk of NAFLD the reported prevalence of 
liver fibrosis ranged from 0% - 92.6% (see appendix p3). Again, the prevalence varied dependent on 
the non-invasive test which was used and the degree of liver fibrosis that was being estimated. In the 
5 studies which estimated any liver fibrosis the prevalence ranged between 0.4%-92.6%. The studies 
which reported the highest estimates of prevalence were Williamson et al(26) and Morling et al(27) in 
which 100% of the study populations were reported to have type 2 diabetes. Four studies estimated 
the prevalence of advanced liver fibrosis which ranged from 0%-27.9%. The highest estimate was 
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obtained from Vesey et al(21) who only recruited patients aged over 65 years, therefore increasing the 
probability of disease being identified. The lowest estimate was obtained in the study by Wong et 
al(20) who utilised several non-invasive tests to demonstrate the prevalence of advanced liver fibrosis. 
In this cohort, use of the NAFLD fibrosis score≥0.676 and APRI≥1.5 estimated a 0% prevalence for 
advanced fibrosis, while using TE≥9.6kPa and AST:ALT ratio≥1.0 the  prevalence increased to 3.7% and 
12.1% respectively. 
 
ALD 
 
In the four studies which stratified patients identified to be at risk of ALD the reported prevalence 
ranged between 11%-20.5% (see appendix p3). In the three studies(19, 28, 29) which utilised TE the 
reported disease prevalence was similar despite two different thresholds being chosen and the 
reported outcome measures being different.  
Prevalence of cirrhosis 
 
Only seven studies reported the prevalence of cirrhosis which varied depending on the study 
population being stratified (Table 3). In the four studies which used subjects from the general 
population the reported prevalence varied between 0.1%-1.7%. The highest estimate was obtained by 
Malik et al(24) but they did not report the risk factor prevalence in the study population. It cannot 
therefore be determined why this self-selected group were at increased risk of having clinically 
significant liver disease. The other three studies which stratified patients due to an underlying risk 
factor reported a prevalence of 2.4%-4.0%; a much higher estimate of liver cirrhosis prevalence 
compared to studies of the general population. Interestingly, in the study by Das et al(30) which 
reported a cirrhosis prevalence of 2.4% in patients with NAFLD, the prevalence of cirrhosis in their 
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unselected cohort was calculated to be 0.2%; equivalent to the estimates reported in the other studies 
of the general population.  
 
Liver biopsy results 
 
Only six studies utilised histology on liver biopsy to confirm the diagnosis of liver fibrosis/cirrhosis as 
indicated by the non-invasive test (Table 4). This includes 5 studies which used TE, all of which used 
different thresholds of liver stiffness, and 1 study which used Fibrotest. Within no study were liver 
biopsies completed in all of the patients undergoing the non-invasive test.  
 
Across the 6 studies, the acceptance rate of liver biopsies varied between 22.5%-87.5%. In the study 
by Roulot et al(31) the acceptance rate was 100% in the 9 patients who had a liver stiffness reading 
>13kPa, all of whom were confirmed to have a histological diagnosis of cirrhosis. However, in 
comparison, in the study by Moessner et al(28) who used a similar liver stiffness threshold of 12kPa, 
only 20/45 (44.4%) patients accepted a liver biopsy and only 9/20 (45%) were confirmed to have a 
histological diagnosis of cirrhosis. The other patients were identified to have varying degrees of liver 
fibrosis (4/20 = F1 fibrosis, 3/20 = F2 fibrosis, 4/20 = F3 fibrosis). Importantly, this cohort had an 
underlying risk factor of hazardous alcohol use for which a higher liver stiffness threshold is proposed 
to predict advanced fibrosis and cirrhosis compared to other aetiologies(32, 33).  
    
ALT levels and predictors of significant liver disease  
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Nine studies have reported the percentage of patients with an abnormal test result who had normal 
ALT levels. This indicates the percentage of patients who would traditionally not have been identified 
though current referral algorithms which are based upon abnormal LFTs. Two studies by Wong et 
al(20) and Grattagliano et al(34) used conservative ALT levels of >19IU/L for women and >30IU/L for 
men as suggested by Prati et al(35) whilst the remaining studies used the more traditional cut offs.   
 
The percentage of patients with liver fibrosis who had a normal ALT level in the studies of the general 
population ranged from 40%-74.6% and in those which identified patients with an underlying risk 
factor ranged from 26.5%-87.5% respectively. The lowest estimates reported within both ranges were 
seen within the two studies which utilised the more conservative cut offs. Of the three studies which 
used traditional cut offs in the patient populations with an underlying risk factor, 72.4%-87.5% of 
patients had a normal ALT level and would not have been routinely identified.   
 
Harman et al(29) was the only study which reported the percentage of patients with a normal ALT 
level who were diagnosed with cirrhosis. In this study 90.9% of patients with asymptomatic 
compensated cirrhosis would not have been identified via traditional community based algorithms.  
 
Predictors of clinically significant liver disease 
Five studies completed a multivariate analysis to identify the variables which independently predict an 
outcome of elevated liver stiffness using TE or significant/confirmed fibrosis from a non-invasive test 
result (see appendix p4). The key variables identified include a raised BMI, an elevated waist 
circumference), an abnormal ALT, the age of the patient and being male. 
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Discussion 
 
This review has demonstrated that a number of non-invasive tests have the ability to stratify for the 
severity of liver disease within a community setting.  Moreover, when compared to the uptake of 
other screening programs, the participation of those invited suggests that as screening tests for use in 
the community they are acceptable to patients. The estimates of cirrhosis prevalence (0.1%-1.7%) are 
greater than previously reported (0.07-0.13%)(36,37) highlighting the burden of undiagnosed chronic 
liver disease in the general population and that the true population prevalence is still yet to be 
established. The presence of normal liver function tests in both significant liver disease (ranging from 
41% to 75 %) and cirrhosis (90 % in one study) is a stark reminder of the limitations of these tests to 
detect chronic liver injury.   
 
 In this review eleven different non-invasive tests were used within heterogeneous population groups. 
The variation in reported disease prevalence highlights the uncertainty as to which test is most 
appropriate as demonstrated specifically in the studies by Morling et al(27) and Wong et al(20) who 
applied several non-invasive tests to the same cohort of patients resulting in widely differing estimates 
of prevalence for any liver fibrosis (0.4%-63.8%) and advanced liver fibrosis (0%-12.1%) respectively.     
 Moreover, comparing studies which used the same non-invasive test provided no further clarity as 
different thresholds were used for the stratification of liver fibrosis. However, as demonstrated by 
Roulot et al(31) and Moessner et al(28), even when similar liver stiffness thresholds for transient 
elastography were used a wide variation in the histological diagnoses can be observed. The variation 
in thresholds may be a result of using normal populations to determine thresholds. Roulot et al(38) 
defined a threshold of 8kPa, based upon the 95th centile, in a healthy population, in contrast to the 
study by Conti et al which reported the 95th centile at 6.8kPa (39). The differences observed may be 
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due to the younger age of participants in the study by Conti (patients in the cohort were between 30 
and 60 years of age), or the separate analysis of patients with ultrasound evidence of NAFLD and 
hence a lower prevalence of metabolic syndrome risk factors.  The normal thresholds of Fibrotest have 
been defined in healthy blood donors(40) and are consistent with the index validation study using the 
biopsy as a reference standard(41). This demonstrates that the optimal threshold for defining a 
specific degree of liver fibrosis is yet to be agreed.   There also appears to be no concordance over 
which stage of liver fibrosis is clinically important with studies reporting the prevalence of any, 
significant or advanced liver fibrosis as their outcome measure. In NAFLD, it has been shown that 
patients with ≥F3 fibrosis have an increased risk of mortality predominantly from cardiovascular and 
liver related disease(42, 43).  
 
 
It is obvious that use of a liver biopsy as a screening tool is not feasible due to the practicalities of 
performing an invasive procedure in a community setting, the expense and the low prevalence of 
disease; in combination this results in an unfavourable risk/benefit ratio. Currently all non-invasive 
tests continue to be validated against histological findings which have their own well documented 
limitations(44). From the studies within this review the true diagnostic performance could not be 
established as a liver biopsy was not completed on all of the patients with an abnormal test result or 
any patient with a negative test result. Although formal analysis of the quality of included studies was 
not performed as they were in essence diagnostic prevalence studies for which a relevant validated 
quality assessment tool was not found, one must consider all included studies to be at high risk of 
methodological bias due to the inherent selection bias for liver biopsy (where performed). Completion 
of longitudinal cohort studies would enable the true diagnostic performance of a non-invasive test to 
be assessed along with identifying and validating the optimum threshold that should be applied. These 
studies are also imperative given the emerging evidence of the additional prognostic information that 
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these non-invasive markers could provide(14, 42). Boursier et al(45) has recently demonstrated the 
value of using transient elastography in the context of NAFLD to stratify patients into specific 
subgroups which correlate with clinical outcomes. The clinical outcome studies that have emerged, are 
focused on patients presenting to hospitals with the associated limitations of both referral bias and 
spectrum bias. Whilst long term outcomes are awaited from biomarker studies performed specifically 
in a general population setting, the only feasible option is to utilise the extensively validated 
biomarker tests derived from specialist care. This review highlights that caution needs to be exercised 
in extrapolating non-invasive markers for the detection of significant liver disease but greater 
agreement exists in the context of detecting liver cirrhosis.  Notwithstanding the limitations above, 
transient elastography and Fibrotest were the most frequently used tests being utilised within 3 or 
more studies, and had their results compared against histological findings, subsequently making these 
the most validated non-invasive tests in a community population.  
 
Despite liver disease mortality in Europe being comparable to other diseases which are given a higher 
priority on the public health agenda(5), improved detection of early liver disease in the community 
continues to make slow progress and is reportedly restricted by available resources and the 
considerable numbers of patients at risk(46). The studies which reported the presence of any liver 
fibrosis in the general population have demonstrated the potential burden of disease (0.7%-25.7%) 
although more focussed stratification for advanced liver fibrosis (0.9%-2%) or cirrhosis (0.1%-1.7%) 
narrowed estimates of prevalence. To date, there has been no recommendation to screen the general 
population for chronic liver disease due to the concerns about cost and the unknown wider 
consequences of a false positive or negative result. However, with the increasing incidence of risk 
factors such as alcohol misuse, obesity and type 2 diabetes, targeting specific high risk populations 
may initially be more realistic and has recently been recommended by the European Association for 
the Study of Liver (EASL)(46). Studies which targeted patients with risk factors of chronic liver disease 
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reported a higher prevalence of advanced liver fibrosis (0%-27.9%) and cirrhosis (2.4%-4%) in 
comparison to the general population.  Health economic evaluations to determine the cost 
effectiveness of targeting specific patient populations may aid decisions regarding implementation.  
 
Finally, this review demonstrates that the longstanding reliance upon LFTs is misguided and that 
current strategies are ineffective and missing a large proportion of patients with asymptomatic liver 
disease; 26.5-87.5% of patients with an abnormal non-invasive test result had an ALT level within the 
normal range. Strategies which improve risk stratification are urgently required and should not be 
based upon abnormalities within LFTs alone. Targeting patients with known risk factors will improve 
the diagnostic yield and be more effective in identifying patients with asymptomatic chronic liver 
disease. Furthermore, employing a risk stratification algorithm which also incorporates simple patient 
related risk factors such as those identified through the multivariate analysis (raised BMI, elevated 
waist circumference, abnormal ALT, age and gender) could increase the likelihood of identifying 
patients with liver fibrosis.   
 
In conclusion, this systematic review has demonstrated an appreciable burden of undetected chronic 
liver disease within the community setting in a diverse set of populations. Validated non-invasive tests, 
including transient elastography and Fibrotest, consistently detected disease which would have 
otherwise been missed by current referral pathways based upon abnormal liver function tests. The 
diagnostic yield was further enhanced if a risk factor approach was utilised rather than a general 
population screening programme. This review provides a starting point for creating new pathways to 
stratify clinically significant liver disease in a general populations setting.  
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Appendix 
 
Search algorithms used within the electronic databases 
 
Database: Ovid MEDLINE(R) <1946 to January Week 3 2015> 
Search Strategy: 
Results: 329 hits 
-------------------------------------------------------------------------------- 
1     exp Liver Cirrhosis/di [Diagnosis] (7647) 
2     exp Fatty Liver/di [Diagnosis] (3112) 
3     exp Liver Diseases, Alcoholic/di [Diagnosis] (1367) 
4     (hepatic fibrosis or Chronic liver disease* or advanced fibrosis or non alcoholic fatty liver disease* 
or NAFLD or NAFL or alcoholic liver disease* or ALD or liver fibrosis* or hepatic cirrhos* or liver 
cirrhos* or fatty liver disease* or fatty liver or advanced fibrosis).mp. (113886) 
5     exp Biological Markers/ (669858) 
6     exp Elasticity Imaging Techniques/ (3985) 
7     exp Diagnostic Imaging/ (1816061) 
8     (non invasive biomarker* or non invasive biological marker* or non invasive marker* or fibroscan 
or liver stiffness or transient elastography or ultrasound abdomen or ARFI or liver function test* or 
LFT* or fibrotest* or fib4 or Lok or FORNS or APRI or ELF or NFS or BAAT or BARD or noninvasive 
biomarker* or noninvasive biological marker* or noninvasive marker* or elastogram* or 
sonoelastograph* or imaging tissue elastic or elasticity imaging technique*).mp. 
(42847) 
9     exp Family Practice/ or exp General Practice/ (65915) 
10     exp Primary Health Care/ (84294) 
11     exp Community Health Services/ (514681) 
12     (gp or general practice* or family practice* or primary care or communit* or outreach).mp. 
(539188) 
13     1 or 2 or 3 (10904) 
14     5 or 6 or 7 or 8 (2473667) 
15     4 and 14 (23298) 
16     13 and 14 (4877) 
17     9 or 10 or 11 or 12 (962504) 
24 
 
18     15 or 16 (23432) 
19     17 and 18 (329) 
 
Database: Embase <1980 to 2015 Week 03> 
Search Strategy: 
Results: 274 hits 
-------------------------------------------------------------------------------- 
1     exp Liver Cirrhosis/di [Diagnosis] (10375) 
2     exp Fatty Liver/di [Diagnosis] (4932) 
3     exp Liver Diseases, Alcoholic/di [Diagnosis] (1672) 
4     (hepatic fibrosis or Chronic liver disease* or advanced fibrosis or non alcoholic fatty liver disease* 
or NAFLD or 
NAFL or alcoholic liver disease* or ALD or liver fibrosis* or hepatic cirrhos* or liver cirrhos* or fatty 
liver disease* or fatty liver or advanced fibrosis).mp. (172281) 
5     exp Biological Markers/ (136914) 
6     exp Elasticity Imaging Techniques/ (6192) 
7     exp Diagnostic Imaging/ (120239) 
8     (non invasive biomarker* or non invasive biological marker* or non invasive marker* or fibroscan 
or liver stiffness or transient elastography or ultrasound abdomen or ARFI or liver function test* or 
LFT* or fibrotest* or fib4 or LOk or FORNS or APRI or ELF or NFS or BAAT or BARD or noninvasive 
biomarker* or noninvasive biological marker* or noninvasive marker* or elastogram* or 
sonoelastograph* or imaging tissue elastic or elasticity imaging technique*).mp. 
(55678) 
9     exp Family Practice/ or exp General Practice/ (68233) 
10     exp Primary Health Care/ (110827) 
11     exp Community Health Services/ (99163) 
12     (gp or general practice* or family practice* or primary care or communit* or outreach).mp. 
(663151) 
13     exp chronic liver disease/di [Diagnosis] (1122) 
14     exp early diagnosis/ (72202) 
15     exp liver fibrosis/ (26007) 
16     exp diagnosis/ (4570720) 
17     exp non invasive measurement/ (13716) 
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18     chronic liver disease/ (12578) 
19     exp liver cirrhosis/ (109545) 
20     exp fatty liver/ (39198) 
21     exp nonalcoholic fatty liver/ or exp alcohol liver disease/ (31283) 
22     4 or 15 or 18 or 19 or 20 or 21 (185464) 
23     5 or 6 or 7 or 8 or 14 or 17 (389042) 
24     (22 or 1 or 2 or 3) and 23 (17179) 
25     9 or 10 or 11 or 12 (722145) 
26     24 and 25 (274) 
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Table 1. Baseline characteristics of 19 studies included within the systematic review. Listed in order of risk factor for liver disease 
(unselected general population, general population selected by age, NAFLD risk factors, ALD risk factors, risk factors for both NAFLD 
and ALD) 
Study (First 
Author) 
Study Location/Patient 
Selection/Liver Disease 
Risk Factor 
Non-invasive 
Test Utilised 
Total Study 
Population 
No. of Participants 
Screened 
Mean 
Patient Age 
(years) 
Male 
Gender 
(%) 
Baba(19)  
Japan; annual medical 
check-up at community 
health centre; unselected 
(alcohol and NAFLD 
subgroup analyses) 
TE Not Stated 
423 (of whom valid TE 
in 416 (98.3%)); 
subgroups of alcohol 
misuse (n=151) and 
NAFLD (n=58) 
47.4 60.1% 
Wong(20)  
Hong Kong; subjects 
invited at random aged 
18-70 from census 
database; unselected 
(subgroup analysis of 
patients with NAFLD 
(MRS)) 
TE (all); NAFLD 
– AST:ALT ratio, 
APRI, BARD, 
FIB4, NAFLD 
fibrosis score 
3000 
922 (of whom valid TE 
in 759 (82.3%)) 
NAFLD subgroup - 264 
48.0 42.2% 
You(18)  
South Korea; healthy 
subjects attending health 
check at local hospital; 
unselected 
TE Not Stated 
164 (of whom valid TE 
in 159 (97%)) 
56.0 54.7% 
Lemoine(47)  
The Gambia; community 
screening of healthy 
subjects; unselected 
TE Not Stated 
76 (of whom valid TE in 
72 (94.7%) 
49.5 43% 
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Malik(24)  
United Kingdom; subjects 
recruited via advert and 
reviewed in private clinic; 
unselected 
TE Not Stated 116 Not stated 
Not 
stated 
Fabrellas(48)  
Spain; subjects invited at 
random from state health 
registry; age 18-70 years 
TE Not Stated 
502 (Of whom valid TE 
in 495 (98.6%) 
47.2 41% 
Zelber-Sagi(25)  
Israel; random sample of 
participants of First Israeli 
National Health and 
Nutrition Survey; age 25-
64 years 
Fibrotest 799 
349 (of whom 338 
(96.8%) had valid 
Fibrotest results) 
50.8 54.7% 
Poynard(23)  
France; free medical 
check-up at community 
health centre; age≥40 
years 
Fibrotest, TE Not Stated 
7,554 (of whom valid 
Fibrotest/absence of 
previous liver disease 
in 7,482 (99%)) 
56.9 55.1% 
Roulot(31)  
France; free medical 
check-up at community 
health centre; age>45 
years  
TE Not Stated 
1,358 (of whom valid 
TE in 1,190 (87.6%)) 
57.7 60.5% 
Veysey(21)  
Australia; general 
population screening of 
elderly patients; age ≥65 
years 
NAFLD Fibrosis 
Score 
Not Stated 
440; subgroup of 190 
subjects with NAFLD 
(Fatty Liver Index) 
78.0 40% 
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Armstrong(49)  
United Kingdom; screening 
of subjects with raised ALT 
level from 8 primary care 
practices; NAFLD 
(ultrasound) and raised 
ALT 
NAFLD Fibrosis 
Score (NFS) 
Not Stated 
295 (of whom NFS 
measured in 236 with 
available serum) 
58.0 56.6% 
Kim(42)  
United States; subjects 
from NHANES III general 
population cohort (1988-
1994); NAFLD (ultrasound) 
NAFLD Fibrosis 
Score 
Not Stated 4,083 45.5 50.4% 
Grattagliano(34)  
Italy; subjects from 10 
primary care practices; 
NAFLD (ultrasound) 
Fibrotest Not Stated 259 51.0 63.7% 
Williamson(26)  
Scotland; subjects from 
Lothian Type 2 Diabetes 
cohort (aged 60-74); type 
2 Diabetes 
Hyaluronic acid, 
BAAT, BARD, 
NAFLD fibrosis 
Score 
5,454 
939 (year 1 clinic 
attendees); subgroup 
of 663 with possible 
NAFLD 
68.9 52% 
Morling(27)  
Scotland; subjects from 
Lothian Type 2 Diabetes 
cohort (aged 60-74); type 
2 Diabetes (subgroup 
analysis of patients with 
NAFLD (Ultrasound)) 
TE, ELF Score, 
AST:ALT ratio, 
APRI, FIB4 
5,454 
767 (year 4 clinic 
attendees); subgroup 
of 282 with NAFLD 
71.4 52.8% 
Das(30)  
India; 1 in 3 sample of 
voting registry invited at 
random; NAFLD 
TE 2,406 
44 (out of 1,911 
screened for NAFLD, 
164 were positive and 
44 also had raised ALT) 
39.0 54% 
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(Ultrasound and CT) and 
raised ALT 
Sheron(22)  
United Kingdom; screening 
of subjects from 9 primary 
care practices; alcohol 
(AUDIT score ≥8) 
Southampton 
Traffic Light 
Test 
1,128 393 44.1 58.3% 
Moessner(28)  
Denmark; screening of 
subjects attending drug 
and alcohol outreach 
centre; alcohol misusers 
who were HCV negative 
TE 759 175 Not Stated 
Not 
Stated 
Harman(29)  
United Kingdom; screening 
of subjects from 2 primary 
care practices; hazardous 
alcohol use or type 2 
Diabetes or raised ALT 
TE* 920 
378 (of whom valid TE 
in 366 (96.8%)); 
subgroups of 
hazardous alcohol 
misuse (n=174), Type 2 
Diabetes (n=211) and 
raised ALT (n=54) 
61.8 67.5% 
ALD= Alcoholic liver disease; ALT = alanine aminotransferase; AST = aspartame aminotransferase; APRI = AST:platelet count ratio; AUDIT = Alcohol 
use disorders identification test;  BAAT = score of age≥50 years (1 point), body mass index≥28 kg/m2 (1 point), ALT≥2 times upper limit of normal, 
triglycerides≥1.7mmol/L; BARD = weighted score of Body mass index ≥28kg/m2 (1 point), AST:ALT ratio≥0.8 (2 points), Type 2 Diabetes (1 point); CT 
= Computer tomography; ELF = Enhanced Liver Fibrosis (combination of hyaluronic acid, TIMP metallopeptidase inhibitor 1 and Procollagen III N-
Terminal Propeptide);FIB4 = combination of age, ALT, AST and platelet count; Fibrotest = combination of α2-macroglobulin,age, Apolipoprotein A1, 
bilirubin, gender, GGT and haptoglobin; HCV = Hepatitis C virus; MRS = Magnetic resonance spectroscopy; NAFLD = Non-alcoholic fatty liver disease; 
NHANES III = National health and nutrition examination survey; NFS = NAFLD Fibrosis Score (combination of age, hyperglycaemia, body mass index, 
platelet count, albumin, and AST:ALT ratio); Southampton Traffic Light Test = combination of hyaluronic acid, Procollagen III N-Terminal Propeptide 
and platelet count; TE = Transient Elastography; *=study using TE where XL probe liver stiffness measurement was utilised in selected patients 
(failed M probe measurement or BMI≥35kg/m2). 
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Table 2. Results of 10 studies reporting liver fibrosis prevalence in unselected subjects of the general population or subjects selected by age alone 
using a non-invasive test in a community setting 
Study (First 
Author) 
Risk Factor Prevalence Outcome Measure 
Non-invasive Test 
Threshold   
Disease 
Prevalence 
Normal ALT (%) 
(Diseased State) 
Baba(19)  
BMI≥23 = 33.4% 
Alcohol consumption >20g/day 
= 36% 
Any liver fibrosis 
TE (liver stiffness) 
≥5.9kPa 
14.4% 55% 
Wong(20)  
Type 2 Diabetes = 5.2% 
BMI≥25 = 22.8% 
Advanced Liver Fibrosis 
TE (liver stiffness) 
≥9.6kPa 
2% 40% 
You(18)  
BMI>25 = 41.5% 
Type 2 Diabetes = 11.9% 
Hypertension = 25.2% 
Significant Liver Fibrosis TE (liver stiffness) ≥7kPa 6.9% 63.6% 
Lemoine(47)  Not Stated Any Liver Fibrosis 
TE (liver stiffness) 
≥7.2kPa 
11% Not Stated 
Malik(24)  Not Stated Any Liver Fibrosis TE (liver stiffness) ≥7kPa 19% Not Stated 
Fabrellas(48)  
Hazardous alcohol consumption 
= 9% 
Any Liver Fibrosis 
TE (liver stiffness) 
≥6.8kPa 
5.7% Not stated 
Zelber-Sagi(25)  
Type 2 Diabetes = 6.8% 
Hypertension  37.3% 
i) Any Liver Fibrosis 
ii) Significant Liver Fibrosis 
i) Fibrotest ≥0.22 
ii) Fibrotest ≥0.32 
i) 25.7% 
ii) 12.8% 
Not Stated 
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Metabolic syndrome = 18.6% iii) Advanced Liver Fibrosis iii) Fibrotest ≥0.59 iii) 0.9% 
Poynard(23)  
Hazardous alcohol = 22.5% 
BMI≥27 = 32.5% 
Dysglycaemia = 15.3% 
i) Presumed Liver Fibrosis 
ii) Any Liver Fibrosis 
i) Fibrotest>0.48 
ii) Fibrotest>0.48 and TE 
(liver stiffness) ≥7.1kPa 
i) 2.8% 
ii) 0.7% 
i) 74.6% 
ii) 66% 
Roulot(31)  
Metabolic syndrome = 20.3% 
BMI≥30 = 17.1% 
BMI 25-29 = 45.8% 
Any liver fibrosis TE (liver stiffness) ≥8kPa 7.5% 
43% 
 
Veysey(21)  
NAFLD (fatty liver index>60) = 
43.2% 
Any Liver Fibrosis 
NAFLD Fibrosis 
Score>0.676 
18.9% Not Stated 
BMI = body mass index; Fibrotest = combination of α2-macroglobulin,age, Apolipoprotein A1, bilirubin, gender, GGT and haptoglobin; kPa = kilopascals; NAFLD = Non-
alcoholic fatty liver disease; NFS = NAFLD Fibrosis Score (combination of age, hyperglycaemia, body mass index, platelet count, albumin, and AST:ALT ratio); TE = 
Transient Elastography  
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Table 3. Results of 7 studies reporting liver cirrhosis using a non-invasive test in a community setting 
Study (First 
Author) 
Risk Factor 
Prevalence 
Outcome Measure 
Non-invasive Test 
Threshold   
Disease Prevalence 
(% in studied 
population) 
Cirrhosis Aetiology 
Normal ALT (%) 
(Diseased State) 
Malik(24)  Not Stated Cirrhosis 
TE – liver 
stiffness≥7kPa and 
liver biopsy 
confirmation 
1.7% Not Stated Not Stated 
Zelber-Sagi(25)  
Diabetes = 6.8% 
Hypertension = 
37.3% 
Metabolic 
syndrome = 18.6% 
Cirrhosis Fibrotest≥0.75 0.3% Not Stated Not Stated 
Poynard(23)  
Hazardous alcohol 
22.5% 
BMI≥27 – 32.5% 
Cirrhosis 
Fibrotest>0.48 and 
TE (liver stiffness) 
≥7.1kPa and liver 
biopsy confirmation 
0.1% 
NAFLD and ALD 
(44%), NAFLD 
(33%), ALD and 
Hepatitis C (22%) 
Not Stated 
Roulot(31)  
Metabolic 
syndrome = 20.3% 
BMI≥30 – 17.1% 
BMI 25-29 = 45.8% 
Cirrhosis 
TE – liver 
stiffness>13kPa 
0.76% 
Alcohol (56%), 
Chronic viral 
hepatitis (44%) 
Not Stated 
Das(30)  
Whole population: 
BMI≥25 = 7% 
Cirrhosis 
NAFLD (ultrasound, 
CT, TE –liver 
stiffness ≥8.0kPa)  
0.2% of whole 
population; 2.4% of 
those with NAFLD 
NAFLD (100%) Not Stated 
33 
 
Abdominal 
Obesity* =11% 
Dysglycaemia = 
13% 
NAFLD subgroup: 
BMI ≥25 = 25% 
Abdominal obesity 
– 39% 
Dysglycaemia – 
26% 
Moessner(28)  
 
Not Stated Cirrhosis 
TE – liver 
stiffness≥12kPa 
4% ALD (100%) Not Stated 
Harman(29)  
Whole population: 
Obesity = 34.4% 
Metabolic 
syndrome = 31.0% 
Type 2 Diabetes = 
55.8% 
Hazardous alcohol 
use = 46.0% 
Cirrhosis 
TE – liver stiffness 
>13.0kPa 
3.0% 
ALD (18.2%) 
NAFLD (81.8%) 
90.9% 
ALD= Alcoholic liver disease; ALT = alanine aminotransferase; BMI = Body Mass Index; CT = Computer tomography; Fibrotest = combination of α2-macroglobulin,age, 
Apolipoprotein A1, bilirubin, gender, GGT and haptoglobin; kPa = kilopascals; NAFLD = Non-alcoholic fatty liver disease; TE = Transient Elastography  
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Table 4. Results of 6 studies reporting liver biopsy findings in patients with an abnormal non-invasive test result 
Study (First 
Author) 
Non-invasive Test Threshold   Biopsy performed Biopsy Results Disease Aetiology 
Lemoine(47)  TE (Liver Stiffness)≥7.2kPa 7/8 (87.5%) 
All F0-F1 fibrosis stage 
(individual staging not 
stated) 
Not Stated 
Malik(24)  
i) TE (Liver Stiffness) 7-10kPa 
ii) TE (Liver Stiffness) >10kPa 
i) 7/18 (38.9%) 
ii) 4/4 (100%) 
i) No fibrosis 7/7 (100%) 
ii) F3 Fibrosis 2/4 (50%), 
Cirrhosis 2/4 (50%) 
All patients ALD or 
NAFLD, but exact 
percentages not 
stated 
Roulot(31)  
i) TE (Liver Stiffness) 8-13kPa 
ii) TE (Liver Stiffness) >13kPa 
i) 18/80 (22.5%) 
ii) 9/9 (100%) 
i) 17/18 (94%) F1 or F2 
fibrosis 
ii) 9/9 (100%) Cirrhosis 
i) NAFLD (8), ALD (6), 
HBV (2), HCV (1), PBC 
(1) 
ii) ALD (5), HCV (3), 
HBV (1) 
Grattagliano(34)  Fibrotest ≥0.58 16/34 (47.1%) 
F2 Fibrosis 2/16 (12.5%) 
F3 Fibrosis 14/16 (87.5%), 
Not Stated 
Moessner(28)  TE (Liver Stiffness)≥12kPa 20/45* (44.4%) 
F1 Fibrosis 4/20 (20%) 
F2 Fibrosis 3/20 (15%) 
F3 Fibrosis 4/20 (20%) 
Cirrhosis 9/20 (45%) 
Not Stated 
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Harman(29)  TE (Liver stiffness)≥8kPa 25/98 (25.5%) 
Hepatic fibrosis 20/25 
(80%) 
No fibrosis 5/25 (20%) 
Not stated 
*Biopsy data reported in this study includes both Hepatitis C positive and negative patients. ALD = alcoholic liver disease; Fibrotest = combination 
of α2-macroglobulin,age, Apolipoprotein A1, bilirubin, gender, GGT and haptoglobin; HBV = Hepatitis B Virus; HCV = Hepatitis C; kPa = kilopascals; 
NAFLD = Non-alcoholic fatty liver disease; PBC = primary biliary cirrhosis; TE = Transient Elastography  
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Section/topic  # Checklist item  
Reported 
on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and 
implications of key findings; systematic review registration number.  
3 + 4 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  5 + 6 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
6 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
n/a 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, giving rationale.  
7 + 8 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
7 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated.  
25 + 26 
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Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).  
9 + 10 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes 
for obtaining and confirming data from investigators.  
9 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
7 + 8 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 
done at the study or outcome level), and how this information is to be used in any data synthesis.  
n/a (see 
page 19) 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  9 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency 
(e.g., I2) for each meta-analysis.  
9 
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Section/topic  # Checklist item  
Reported 
on page #  
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating 
which were pre-specified.  
 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at 
each stage, ideally with a flow diagram.  
9 + 10 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations.  
27, table 
1 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).   
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
30-38 
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5 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  N/A 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).   
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).   
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy makers).  
16-19 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
16-17 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  16-19 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the 
systematic review.  
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From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): 
e1000097. doi:10.1371/journal.pmed1000097  
For more information, visit: www.prisma-statement.org.  
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